Cholera Clinical Trial
Official title:
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
Manufacturers of oral cholera vaccine (OCV) recommend a 7- or 14-days interval between two doses. To carry out two rounds of mass vaccination within this delay is not always feasible and many campaigns implemented to date have used a longer interval. Recent evidence indicates that an extended interval between OCV doses might result in equivalent seroconversion rates and in an improved boosting of mucosal immune responses following the second dose. To guide future OCV vaccination campaigns and improve cholera prevention, it is important to demonstrate the non-inferior immune response of an extended interval between OCV doses. The Investigators aim to demonstrate the non-inferiority of the humoral immune response between individuals receiving a second Euvichol-Plus® pre-qualified OCV dose either 6 or 12 months after the initial dose and individuals receiving a second pre-qualified OCV dose 14 days after the initial dose. The humoral immune response will be assessed as the post-vaccination titer of serum vibriocidal antibodies at 14 days post-2nd dose vaccination. Secondary outcomes include the comparison of the overall rate of vibriocidal seroconversion 14 days after either the first or the second vaccine dose. A subsample of individuals ≥ 18 years will have additional serological evaluation to characterize the kinetics of their antibody responses up to 6 months after the second OCV vaccine dose. Although the vaccine has an established and safe profile, occurrence of adverse events and serious adverse events following vaccination will be assessed (safety evaluation). The study will be an open-label, randomized, controlled, non-inferiority immunogenicity trial comparing the humoral immune responses to OCV in two interventions arms (6 and 12 months interval between OCV doses) compared with a control arm (standard 14-day interval). In each arm, the aim is to recruit 152 individuals aged 1 to 40 year-old eligible for OCV vaccination from the general population (ie. 456 individuals in total). The sub-sample allowing characterizing the kinetics of the humoral response up to 6 months after the administration of the second dose will include 38 participants in each intervention and control arm, among the participants aged ≥ 18 years. In total, 456 individuals will be recruited. The study will be conducted in Conakry, in the Republic of Guinea. Participants will be primarily enrolled in the commune of Dixinn on a voluntary basis. All participants in the intervention and control arms will be invited to a first visit for assessment of eligibility and 1st OCV dose, followed by a visit 14 days after the 1st OCV dose for blood sampling. According to the study arm, the 2nd OCV dose will be administered at 14 days, 6 months or 1 year after the 1st dose and will be followed by a visit 14 days later for blood sampling. Participants in the sub-study will be invited to additional study visits (up to twelve visits in total) for blood sampling. At each visit, blood will be drawn for immunologic analyses. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01895855 -
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
|
Phase 3 | |
Completed |
NCT01339845 -
Introduction of Cholera Vaccine in Bangladesh
|
N/A | |
Recruiting |
NCT05829772 -
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
|
||
Completed |
NCT04760236 -
Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™
|
Phase 3 | |
Recruiting |
NCT04326478 -
Single Dose Azithromycin to Prevent Cholera in Children
|
Phase 2 | |
Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
Completed |
NCT02928341 -
Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
|
N/A | |
Completed |
NCT02864433 -
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
|
||
Recruiting |
NCT06003816 -
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
|
N/A | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Not yet recruiting |
NCT06455852 -
Correlates of Protection for Cholera
|
N/A | |
Completed |
NCT04150250 -
Cholera Anti-Secretory Treatment Trial
|
Phase 2 | |
Terminated |
NCT00624975 -
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
|
Phase 2 | |
Completed |
NCT00226616 -
Zinc Supplementation in Cholera Patients
|
Phase 3 | |
Completed |
NCT03373669 -
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
|
Phase 4 | |
Completed |
NCT02100631 -
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
|
Phase 3 | |
Completed |
NCT02094586 -
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
|
Phase 3 | |
Completed |
NCT01823939 -
PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera
|
Phase 1 | |
Completed |
NCT01365442 -
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
|
N/A | |
Completed |
NCT00128011 -
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
|
Phase 2 |